Why Is AURINIA PHARMACEUTIC Equity (AUPH) Stock Moving Today?

AUPH stock surged 9.31% to $17.68 in a sharp intraday rally driven by the resolution of patent litigation with Teva Pharmaceuticals. The settlement secures exclusivity for Aurinia’s drug voclosporin until at least 2036 and affirms the validity of key patents. The agreement removes a near-term competitive threat and supports the company’s long-term revenue outlook.

What Happened

Aurinia Pharmaceuticals announced a settlement with Teva that prevents the generic version of its drug LUPKYNIS from entering the U.S. market until December 2036. The agreement resolves litigation over Teva’s application to market a generic version of voclosporin, a key revenue driver for Aurinia. The settlement also covers 7.9 mg capsules and confirms the strength of Aurinia’s patent portfolio. The news was filed with the SEC in an 8-K on August 19 and was widely reported in the financial press. The stock opened with a 1.4% gap up and climbed steadily through the morning, reaching a high of $17.80 before settling at $17.68.

What The Data Shows

The stock’s intraday performance reflects strong investor confidence, with volume reaching 0.4 million shares, or 30% of the 3-month average. AUPH is currently trading near its 52-week high of $19.25 and has printed seven fresh 52-week highs on the day. The CEO, Kevin Tang, has added to his position with $12.5 million in insider purchases over the last 90 days, signaling alignment with long-term shareholders. The company’s fundamentals remain strong, with a P/E of 7.0, revenue growth of 19.8% in the trailing twelve months, and a net margin of 100.8%.

What To Watch

Aurinia is set to report its full-year 2026 sales results in the coming months. Investors should monitor coverage breadth and any further developments in patent litigation, as well as the company’s ability to meet its $315 million to $325 million revenue guidance.

Why is AUPH stock moving today?

AURINIA PHARMACEUTIC Equity (AUPH) is drawing unusual attention today. Our newswire has captured 1 story on AUPH across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 50/100). The most recent driver: "AUPH Trading Strategies for Aurinia Pharm Ord Stock" (Barchart).

Is AUPH a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of AUPH coverage reads 50/100 over 1 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.